CAPhO Connections Podcast

Could the secret to optimizing immunotherapy success lie in the gut flora? Emerging research reveals how the microbiome influences cancer treatment response, toxicity, and overall health outcomes. Join us as we explore how gut health, immune checkpoint inhibitors (ICIs), and pharmacy practice are coming together to transform cancer care. Get ready to rethink the future of immunotherapy from the inside out!Learning Objectives:Explore the influence of the gut microbiome on immune checkpoint inhibitor (ICI) efficacy, toxicity, and overall immuno-oncology outcomes, with a focus on emerging evidence.Evaluate the impact of gut-disrupting factors, including antibiotics, proton pump inhibitors, and other medications on ICI treatment response and adverse events.Discuss current and emerging microbiome modulation strategies, such as dietary interventions, prebiotics, probiotics, and fecal microbiota transplants, to enhance ICI outcomes and manage toxicity.Identify practical recommendations for oncology pharmacists to promote microbiome health through medication stewardship, dietary counseling, and collaboration with the care team to optimize ICI therapy.About the Guest: Dr. Arielle Elkrief:Dr. Arielle Elkrief MD, FRCPC is a clinician-scientist and Assistant Professor in the Department of Oncology at the Centre hospitalier de l’Université de Montréal (CHUM). She was recruited to the CRCHUM in 2023 and directs her research laboratory focused on the gut and tumor microbiome as a biomarker of response to immunotherapy. She is also co-Director of the CHUM Microbiome Centre where she leads microbiome-centered clinical trials combining microbiome interventions such as fecal microbiota transplantation (FMT), prebiotics, and diet. In addition, she contributed to establishing the negative impact of antibiotics on immunotherapy activity in patients with cancer. She was recently awarded the American Society of Clinical Oncology Young Investigator Award and the Society of Immunotherapy of Cancer-Melanoma Research Alliance Women in Melanoma Award.

Pediatric oncology pharmacy calls for precision, compassion, and innovation to deliver safe, effective, and personalized care for young patients battling cancer. In Ontario, care is uniquely coordinated through the Pediatric Oncology Group of Ontario (POGO), supporting equitable access to specialized therapies and clinical trials. This episode takes a closer look at acute lymphoblastic leukemia (ALL), the most common childhood cancer, and explores how pharmacists navigate complex dosing, formulation challenges, and evolving treatments. Discover how oncology pharmacists shape hope, transform therapy, and change the lives of young patients and their families.Learning Objectives:- Describe how pediatric oncology care is coordinated through the Pediatric Oncology Group of Ontario (POGO) and its impact on equitable access to specialized treatments and clinical trial participation across the province.- Explain how treatment design is tailored and influenced, including the use of intensive regimens, off-label therapies, and long-term survivorship planning.- Outline the key phases of acute lymphoblastic leukemia (ALL) treatment and discuss how evolving risk stratification and the introduction of agents such as blinatumomab have changed pharmacy practice, including drug administration, monitoring, and funding considerations.- Identify strategies pharmacists use to monitor, prevent, and manage early and long-term toxicities, such as steroid-induced myopathy and vincristine-induced neuropathy and to collaborate with multidisciplinary teams.- Discuss the future of pediatric oncology pharmacy, including innovations in molecularly targeted and immune-based therapies, and the pharmacist’s role in advancing access, safety, and advocacy for young patients and their families.Podcast Guest: Matthew Bui

Artificial Intelligence(AI) has the potential to transform oncology pharmacy by offering powerful tools to streamline workflows, support clinical decision-making, optimize treatment planning, and enable safer, more personalized care. However, with great potential comes important challenges related to regulation, reliability, and the need for ongoing professional development. Tune in as we explore the opportunities, limitations, and evolving impact of AI in cancer pharmacy practice!Learning Objectives:Examine the impacts of artificial intelligence (AI) on oncology pharmacists in supporting clinical decision-making and workflow efficiencyAnalyze key regulatory issues related to AI integration in oncology pharmacy, including impacts on clinical roles and data privacy in patient careExplore the challenges and opportunities AI presents for the professional development and future skills of oncology pharmacistsGuests:Bastiaan BuijtenhuijsBastiaan is Head of Product at iQ HealthTech and ProductOwner for iQemo, a leading SACT prescribing system used in the UK and internationally. He completed the NHS Digital Academy (Cohort 3) and MSc in AI for oncology pharmacy, and has recently begun a PhD in applied clinical AI.Sean HopkinsSean Hopkins is a pharmacist with more than 25 years of experience in hospital pharmacy, including over 20 years in outpatient ambulatory oncology clinics. He has served as a front-line pharmacist at The Ottawa Hospital Cancer Centre, worked as a Breast Cancer Clinical Specialist for three years, and later became the Professional Practice Coordinator for Oncology Pharmacy. He also served as the Manager of Oncology Pharmacy at the Simcoe Muskoka Regional Cancer Program at the Royal Victoria Regional Health Centre, where he additionally held an interim role as Director of the Cancer Program during the recruitment of a permanent Director. He is currently the QI Pharmacist at Sunnybrook Health Sciences Centre.

In Part 1 of our medical cannabis in cancer series, guest Marie Parish discussed the rising interest of patients with cancer to explore and use cannabinoids medicinally, shedding light on emerging dosage forms and providing practical education points for patients. Oncology pharmacists are positioned optimally to help patients with cancer navigate medical cannabis or find reliable information about it. In this Part 2 episode, Carlo De Angelis will take you inside Sunnybrook’s pharmacist-led Cannabis Consultation Service, which has been in existence since 2019. Join us for an insightful episode where Carlo’s expertise shines! He delves into the motivations driving patients' interest in medical cannabis, highlights key safety considerations, and shares practical strategies to support responsible cannabis use. Discover the intricacies of implementing a pharmacist-led, patient-centred cannabis consultation service, as Carlo discusses both its challenges and triumphs. If you’re in oncology pharmacy and looking to deepen your understanding of this evolving area in cancer care, this episode is a must-listen!Learning Objectives:Explore why cancer patients may be increasingly curious about plant-based cannabinoids and explore the specific symptoms or side effects they hope to manageDescribe the structure of the Cannabis Consultation Service, including referral pathways, standardized assessment tools, team roles, typical titration, and follow up practicesExamine the processes of implementing a pharmacist-led cannabis consultation service in an institution, from selecting suitable products to addressing clinician hesitancy, evidence gaps, and patient safety concerns.Consider how cannabis evidence generation and broader collaboration may evolve cancer care symptom management over the next decadeEstablish the role of the oncology pharmacist for patients using medical cannabis, and justify why a pharmacist-led service addresses many gaps in carePublication: Marchese M, Zhu C, Charbonneau LF, et al: Description and disposition of patients with cancer accessing a novel, pharmacist-led cannabis consultation service. JCO Oncol Pract 18:e1777-e1786, 2022

Cannabis use among cancer patients is rapidly expanding in both popularity and complexity, creating exciting challenges and opportunities for oncology pharmacists. From understanding a growing variety of product types to interpreting evolving clinical evidence on symptom relief, drug interactions, and treatment outcomes, pharmacists are essential in ensuring safe, personalized patient care. In this episode, we reveal practical insights to empower oncology pharmacists in assessing, counseling, and monitoring patients using cannabis. Discover how this emerging therapy is reshaping oncology practice and could become a game changer!By the end of the podcast, listeners will be able to:Explain the rising use of recreational and medicinal cannabis among cancer patients.Recognize the diverse variety of cannabis product types and their relevance to oncology symptom management.Assess the potential impacts of cannabis on cancer treatments, including drug-drug and drug-disease interactions, safety, and therapeutic outcomes.Summarize current available evidence and data for cannabis use in managing oncology-related symptoms such as nausea, vomiting and pain.Explore practical approaches for oncology pharmacists to evaluate, counsel, and monitor patients using or inquiring.Resource list:1. Bar-Sela G et al. Cannabis Consumption Used by Cancer Patients During Immunotherapy Correlates with Poor Clinical Outcome. Cancers 12:2447, 2020.2. Grimison P, et al. Oral THC:CBD Cannabis Extract for Refractory Chemotherapy-Induced Nausea and Vomiting: A Randomized, Placebo-Controlled, Phase IICrossover Trial. Ann Oncol. 2020 Nov;31(11):1553-1560.  Bar-Lev Schleider L, et al. Prospective Analysis of Safety and Efficacy of Medical Cannabis in Large Unselected Population of Patients with Cancer. Euro J of Int Med. 2018 Mar;49:37-43.3. Khoj L, et al. Effects of Cannabis Smoking on the Respiratory System: A State-of-the-Art Review. Respir Med. 2024 Jan;221:107494.4. Lopera V, Rodríguez A, Amariles P. Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review. J Clin Med. 2022 Feb 22;11(5):11545. Sauer MA et al. Marijuana: Interaction with the Estrogen Receptor. J Pharmacol Exp Ther 224:404-407, 1983.6. Taha T et al. Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies. Oncologist 24:549, 2019.7. Worster B, Hajjar ER, Handley N. Cannabis Use in Patients With Cancer: A Clinical Review. JCO Oncol Pract. 2022 Nov;18(11):743-749. 

What skills and attitudes qualify me to be an oncology pharmacist? Join 2 authors of CAPhO’s new Competencies for Oncology Pharmacists in Canada to explore the 5 pillars of oncology pharmacist competencies. Listeners can reflect on their oncology knowledge and skillset and use the Competencies to advance pharmacy practice.By the end of the podcast, listeners will be able to:Highlight why CAPhO created a collection of the knowledge, skills, and attitudes required to be an oncology pharmacist in Canada.List 4 competencies expected of an oncology pharmacist in Canada.Describe 3 practical ways in which an oncology pharmacist can use the Competencies document intheir practice.

The ISOPP CAPhO 2025 Symposium took place from April 3-7th in beautiful Victoria, British Columbia, Canada. Delegates from all over the world travelled to participate, learn, and network, including Lindon Lin, from Australia. In this episode, Lindon will share their experience from an international lens, including differences in practices and what they took away from the symposium that could be shared locally.Learning Objectives:• Explain why CAPhO ISOPP was chosen to attend• Reflect on the overall experience at CAPhO ISOPP in Victoria BC earlier this month• Highlight symposium takeaways from an International delegate• Discuss global oncology pharmacy practice from an Australian perspective

The ISOPP CAPhO 2025 Symposium will take place from April 3-7th in beautiful Victoria, British Columbia, Canada. With participants coming from over 25 countries, you can expect Victoria to have a different feel than our annual CAPhO Conferences.The international ISOPP template will gather pharmacists and pharmacy technicians from around the world to showcase their practices. We are seeing interesting innovations coming forward that could benefit others in their local communities. It will be an exciting event!About the Author: Tina CrosbieTina Crosbie has been a clinical hematology pharmacist at the Ottawa Hospital for over 25 years and at Extend Pharmacy for the past 6 years.Her research aims to optimize drug administration and enhance patient education. Tina evaluates pharmacy education programs for CCCEP and actively volunteers for CAPhO. She is the chair of the upcoming ISOPP CAPhO 2025 Symposium in Victoria, BC.

When it comes to vaccine-preventable illnesses in patients with cancer, an ounce of prevention is worth a pound of cure! Listen to our podcast to learn how pharmacy professionals can help promote this public health measure in our highly vulnerable population.    Learning Objectives: Describe current recommendations for specific immunizations in patients receiving treatment for cancer Discuss considerations for immunizations in patients with cancer with respect to timing around treatment Understand the role of the pharmacist in ensuring patients are up to date on vaccines About the Author: Irina Rajakumar

“In learning you will teach, and in teaching you will learn” – Phil Collins.  This simple song lyric couldn’t be more representative of oncology pharmacy.  The pace of advancement in this field requires the need for constant learning. We will explore how we can harness our expertise and ability to learn to become the teachers needed for others to excel in this area. Learning Objectives: Explore the relationship between teaching and learning Appreciate why teaching is a necessary role for oncology pharmacy professionals Stimulate reflection on one’s own personal learning and teaching philosophy About the Author: Melanie Danilak

AML treatment options have exploded in the past 10+ years including the approval of different regimens in the non-intensive management of the disease. This podcast will review current practices and considerations for infection prevention for patients treated with myelosuppressive AML regimens. Learning Objectives: Describe the epidemiology, pathophysiology, and prognostic factors in the non-intensive management of AML Review the Canadian Landscape with a focus on current and emerging treatment options for the non-intensive management of AML Discuss current antimicrobial prophylaxis practices at different North American Oncology Centres Review current evidence for infection prophylaxis and drug interaction management in this population Review monitoring, following up and supportive care considerations for the Canadian Pharmacist About the Author: Jonathan Stevens

AINV is a common dose limiting toxicity that can impact adherence and quality of life. Pharmacists are in an ideal position to optimize management. Learning Objectives: Describe the pathophysiology of AINV Apply recommendations from practice guidelines to the treatment of patients with AINV Recognize challenges with completing AINV assessment using patient examples Explain the importance of the multidisciplinary approach to AINV management

When pharmacists provide education about oral chemotherapy medications, there are often recommendations regarding food around administration. This can lead to questions from patients about the well-known myth that sugar feeds cancer cells. Listen to an oncology dietitian as she provides tips on having discussions about sugar and cancer with your patients. Learning Objectives: Discuss the origin of the myth that sugar causes cancer (or that myth that patients with cancer must avoid sugar) Review the evidence behind dietary intake of sugar and incidence of cancer or cancer outcomes Provide tips for having effective discussions with patients regarding this topic Review dietary recommendations for patients undergoing cancer treatment About the Author - Grace Beda: Grace completed her bachelor's and master’s degrees in human nutrition at the University of Guelph in 2013, and has since worked as a Registered Dietitian for 10 years in Calgary, Alberta. She spent the first 5 years of her career in acute and tertiary care hospitals, covering a wide range of wards from general medicine to surgery and ICU. She transitioned to outpatient oncology 5 years ago at the Tom Baker Cancer Centre in Calgary in the GI radiation clinics, then spent a year at the Red Deer Cancer Centre as the only oncology dietitian where she provided 1 on 1 consultation for patients from every tumor group. She moved back to the Tom Baker in 2020, working in the Head and Neck radiation clinics, then moved to malignant hematology and specifically bone marrow transplants in 2021, where she has happily settled in as part of a diverse multidisciplinary team in the Southern Alberta Blood and Marrow Transplant Program. References: Alberta Health, Alberta Government, Alberta Health Services. (2015, May 1). ABOUT 4 IN EVERY 10 CANCERS IN ALBERTA ARE CAUSED BY FACTORS THAT WE CAN CHANGE. Retrieved from healthiertogether.ca: https://www.healthiertogether.ca/health-conditions/cancer/ Arends, J. e. (2017). ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition, 36:11-48. Dashty, M. (2013). A quick look at biochemistry: Carbohydrate metabolism. Clinical Biochemistry, 46:1339-1352. FAO. (2011). Dietary Protein Quality Evaluation in Human Nutrition. Auckland, New Zealand: Food and Agriculture Organization of the United Nations. Fenton, T. H. (2016). Systematic review of the association between dietary acid load, alkaline water and cancer. BMJ Open, 6(6): e010438. Ford, K. A. (2022). The importance of protein sources to support muscle anabolism in cancer: An expert group opinion. Clinical Nutrition, 41:192-201. Gallagher, E. L. (2020). Hyperinsulinaemia in cancer. Nat Rev Cancer, Nov;20(11):629-644. Hamaguchi, R. I. (2022). Clinical review of alkalization therapy in cancer treatment. Front Oncol, 12: 1003588. Liberti, M. L. (2016). The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci, Mar; 41(3): 211–218. Mintziras I, M. M. (2018). Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: systematic review and meta-analysis. Int J Surg , 59:19–26. Prado, C. L. (2022). Examining guidelines and new evidence in oncology nutrition: a position paper on gaps and opportunities in multimodal approaches to improve patient care. Supportive Care in Cancer, 30:3073–3083. Vigneri, R. S. (2020). Rethinking the Relationship between Insulin and Cancer. Trends Endocrinol Metab, Aug;31(8):551-560. Xiao J, C. B. (2020). Association of low muscle mass and low muscle radiodensity with morbidity and mortality for colon cancer surgery. JAMA Surg, 155:942–949. Zhang, A. W. (2021). Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes Metab J, May; 45(3): 285–311.

For geriatric cancer patients with multiple comorbidities, the management of cancer may present many therapeutic challenges, so treatment should be tailored to this demographic. Learning Objectives: Discuss the need and role of (GA) Geriatric Assessment for older patients with cancer.  Explain what GA is. Introduce tools used in GA. Highlight the role of pharmacists in geriatric oncology and medication review for older patients.

Hear from CAPhO's Research Committee Chair Tiffany Nguyen in the latest British Oncology Pharmacy Association (BOPA) "Let's Talk About SACT" Podcast Episode. In this episode Tiffany Nguyen sheds light on a variety of research projects currently happening in Canada. Topics include pharmacists managing patients treated with ICIs, a community pharmacy engagement initiative for oral anticancer drugs, research in climate stewardship, as well as international collaboration on research projects. A very special thanks to BOPA for hosting and developing the episode! To learn more, please visit the episode on BOPA's website

ICIs are increasingly being used in the management of oncologic conditions. Although it provides an effective treatment option with the opportunity for long-term positive outcomes, it has the potential for autoimmune toxicities with a variable and prolonged time course. Tune in to hear how the pharmacist can play a key role in imAE management in patients receiving ICIs. The Topic of Episode 12: Immune Checkpoint Inhibitor (ICI) Management. Learning Objectives: Summarize the spectrum of immune mediated adverse events (imAE) with ICIs and apply management principles using the five pillars of imAE management Discuss challenges with identification and management of imAEs with combination therapy such as ICI + TKIs Review clinically relevant pharmacodynamic drug interactions with ICIs and with practical management tips Describe the role of the pharmacist in caring for patients receiving ICIs Glenn Myers is a pharmacist with a focus in outpatient medical oncology at the Dr. Sheldon H Rubin Oncology Clinic in Moncton, New Brunswick. Glenn completed a BSc (Pharmacy) at Dalhousie University in 2011 and subsequently went on to complete his hospital residency at the Saint John Regional Hospital in New Brunswick. Glenn has been practicing in ambulatory oncology for over 10 years and focuses on clinical assessment and management of chemotherapy, oral anti-cancer and immune related adverse effects in patients with cancer. Glenn maintains an active role as the chair of the sponsorship committee with the Canadian Association of Pharmacy in Oncology (CAPhO). Glenn’s other professional interests include teaching and mentoring various levels of pharmacy learners, providing practical education to healthcare professionals, working with retail pharmacies to improve oncology patient care in the community, and performing oncology pharmacy practice-based research to advance the scope of oncology pharmacy.

Bringing a piece of Spain, and lots of practice advancing insights, back to Canada in this post-ISOPP recap from one of the ISOPP Travel Grant award winners. The topic of episode 11: Discussing hot topics from the ISOPP 2023 conference in Seville Spain. Learning Objectives: Provide an overview of the oncology pharmacy burnout plenary session and share major takeaways from the presentation (including resources) Discuss the technology developments influencing your future of pharmacy practice (from those presented at the conference) Discuss the therapeutic innovations and research presented at ISOPP 2023 Highlight the incredible learning opportunities made possible by the CAPhO travel grant program For more information about the podcast, please click here. Guest for this episode: Lauren Hutton Lauren Hutton is the Clinical Coordinator for Oncology Pharmacy at Nova Scotia Health – Central Zone. Lauren completed a BSc(Pharmacy) at Dalhousie University, her hospital residency at The Ottawa Hospital, and subsequently went on to complete her PharmD at the University of Toronto.  Lauren has been practicing in oncology for six years. Her oncology clinical practice areas have included ambulatory medical oncology, acute inpatient palliative oncology, and multiple myeloma ambulatory care. Lauren’s current clinical practice is as an interdisciplinary member of a medical oncology team where she provides care to patients living with prostate cancer receiving treatment with oral anti-cancer therapy.

Although continuing education is an obligation, it doesn’t need to be daunting.  Professional development activities can be engaging, rewarding, and a regular part of your professional routine.  Let’s explore ways to stay motivated and strategies to prioritize your learning.   The topic of episode 7: How to stay up to date in oncology pharmacy Learning Objectives: Identify personal areas of knowledge which require updates Identify resources for continued education in oncology pharmacy Create personal learning goals for continued education Create a plan and schedule for continued education Guest for this episode: Tara Leslie Tara Leslie attained her Bachelor of Science in Pharmacy (BSP) degree from the University of Saskatchewan.  After several years of oncology practice in Calgary, she obtained her Board Certification in Oncology Pharmacy (BCOP) in 2010, acquired her Additional Prescribing Authority (APA) in 2013 and attained a Masters of Education in 2020. In 2017, Tara was the recipient of the Larry Broadfield CAPhO Distinguished Service Award for her commitment to CAPhO and contributions to oncology service.  Currently, she is a Clinical Assistant Professor with the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta where she teaches oncology related curriculum in a variety of courses and is a part of the experiential education team. Tara maintains a clinical practice within an ambulatory hematology/oncology clinic at the Tom Baker Cancer Centre.  She is very passionate about lifelong learning and the important role that pharmacists have in supportive care for people with cancer.  

Oncology drug funding processes impact treatment options available to patients. Frontline pharmacy practitioners have a key perspective and role that allows them to be more engaged in funding processes. The topic of episode 10: How clinical oncology pharmacy team members can become engaged in and help improve drug funding processes Learning Objectives: Describe current Canadian oncology drug funding process Examine the role of frontline clinical pharmacy team members in drug funding Discuss how oncology pharmacy practitioners can become more engaged in and help improve drug funding processes For more information about the podcast, please click here. Guest for this episode: Nicole Kennedy Nicole Kennedy is the Systemic Therapy Manager of Pharmacy Services at Eastern Health, and currently manages oncology therapy funding for the Provincial Cancer Care Program and the Regional Medicine Program. She sits as a representative for NL on the Provincial Advisory Group for pCODR, and also for pCPA. Nicole is currently serving on the Board of Directors for NL’s Pharmacy Board as the hospital representative, as well as on the Board of Directors for CAPhO as Education Committee Chair for Pharmacists – Fundamentals. Nicole obtained her Bachelor of Science in Pharmacy degree at Memorial University in 2015 and went on to complete a Hospital Pharmacy Residency through Dalhousie University in 2016. She obtained her Doctor of Pharmacy degree from the University of Toronto in 2020. Information and additional resources mentioned during this episode of the podcast: Canadian Agency for Drugs and Technologies in Health Drug Access Canada Health Canada: Drug and health product review and approval Institut national d’excellence en santé et en services sociaux (INESSS) Pan-Canadian Pharmaceutical Alliance

Learning Objectives: Describe the role and contributions of the oncology pharmacist to cancer care during the COVID-19 pandemic Discuss the potential complications from COVID-19 in cancer patients, including secondary bacterial and fungal infections Describe the measures (pharmaceutical and non-pharmaceutical) currently available to prevent COVID-19 in cancer patients Identify important and up-to-date resources for pharmacists caring for oncology patients as related to COVID-19 management For more information about the podcast, please click here. Guest for this episode: Miranda So Dr. Miranda So is the Program Lead and Research Director of the Sinai Health-University Health Network Antimicrobial Stewardship Program in Toronto, Ontario. Miranda received her Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees from the Leslie Dan Faculty of Pharmacy, and her Master of Public Health degree in Epidemiology from the Harvard T.H. Chan School of Public Health. Her work focuses on antimicrobial stewardship in immunocompromised patients. Information and additional resources mentioned during this episode of the podcast: The NIH longitudinal study on cancer patients with COVID-19 (NCCAPS) From NCCAPS: Outcome of COVID in cancer patients by vaccination status Clinical outcomes of bacterial, viral and fungal coinfections in cancer patients with COVID the CCC19 consortium study Systematic review/meta-analysis on response to vaccine in immunocompromised patients Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review - ScienceDirect  Canadian data: how COVID impacted timeliness of new cancer diagnosis and treatment: Timeliness and Modality of Treatment for New Cancer Diagnoses During the COVID-19 Pandemic in Canada | Oncology | JAMA Network Open | JAMA Network  Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer | Critical Care Medicine | JAMA Oncology | JAMA Network  Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review  Ontario Health resources page for healthcare professionals  Resource page of American Society of Haematology COVID-19 – US based information